Key facts
- Persist AI’s last known valuation is $42.0M (May 2025).
- It has raised $20.7M; the latest was Early Stage VC ($12.0M) in May 2025.
- Notable investors include Y Combinator, Pioneer Fund, Global Brain, SignalFire, Asymmetry Ventures — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Persist AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Persist AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Persist AI
Developer of AI-enabled cloud formulations intended to accelerate drug development and improve patient lives. The company focuses on using artificial intelligence-driven automation technologies such as automated drug release testing, high-throughput formulation screening, and method transfer and manufacturing scale-up, enabling drug manufacturers to speed up drug formulation.
- Sector
- Healthcare
- HQ
- West Sacramento, CA, United States
- Founded
- 2022
- Employees
- 10
- Website
- persist-ai.com/
- Ownership
- Privately Held (backing)
Persist AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Persist AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Persist AI in its N-PORT filings yet. We sweep new filings monthly.